Taking Aim at Clinical Oncology Market, Proteome Sciences Developing SRM-MS Assay for ER Status
July 22, 2011
Taking Aim at Clinical Oncology Market, Proteome Sciences Developing SRM-MS Assay for ER Status
Recent collaboration agreements between the company and researchers at the Moffitt Cancer Center and the Buck Institute for Research on Aging will further its "intention of building a portfolio of oncology-related assays using selected-reaction monitoring," said an official.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Proteome Sciences, Moffitt Collaborate on Mass Spec Assays for Cancer Studies
July 8, 2011 / ProteoMonitor - Proteome Sciences Inks Deal to Provide Siena Biotech with Protein Biomarker Services
August 12, 2011 / ProteoMonitor - Tohoku U Spinoff Targeting Pharma Industry with SRM-MS Assays for ADMET Research
August 5, 2011 / ProteoMonitor - Hutch, Broad Teams Publish Comprehensive Methods for MS-Based Biomarker Discovery and Verification
July 29, 2011 / ProteoMonitor - Researchers ID Gastric Cancer Biomarker Aimed for Use in DTC Tests in US, China
May 6, 2011 / ProteoMonitor